Consolidation Durvalumab Consistently Improves PFS/OS in LS-SCLC Subgroups
Durvalumab showed consistent PFS and OS benefits vs placebo in LS-SCLC subgroups, regardless of prior PCI and concurrent CRT use, supporting its role as the new standard of care.
Related Clinical Trials
Reference News
Durvalumab showed significant OS and PFS improvements in LS-SCLC patients, regardless of prior PCI or CRT, according to the ADRIATIC trial. OS rates were higher with durvalumab vs placebo, particularly in subgroups receiving carboplatin or twice-daily radiotherapy. Durvalumab's benefit was consistent across PCI and radiotherapy subgroups, supporting its use as a new standard of care in LS-SCLC.
Durvalumab showed consistent PFS and OS benefits vs placebo in LS-SCLC subgroups, regardless of prior PCI and concurrent CRT use, supporting its role as the new standard of care.
Durvalumab improved PFS and OS in LS-SCLC patients with prior PCI, with median PFS of 28.2 months vs 13.0 months in placebo. OS was NR in durvalumab vs 42.5 months in placebo. Benefits were consistent across PCI and radiotherapy subgroups, supporting durvalumab as the new standard of care in LS-SCLC.